131999-28-5
| 中文名称 | 131999-28-5 |
|---|---|
| 中文同义词 | 化合物 5-HT6/7 ANTAGONIST 1 |
| 英文名称 | 1H-Isoindole-1,3(2H)-dione, 2-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]- |
| 英文同义词 | 1H-Isoindole-1,3(2H)-dione, 2-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-;5-HT6/7 antagonist 1 |
| CAS号 | 131999-28-5 |
| 分子式 | C22H20FN3O3 |
| 分子量 | 393.41 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 131999-28-5.mol |
| 结构式 |  |
131999-28-5 性质
| 沸点 | 565.6±50.0 °C(Predicted) |
|---|---|
| 密度 | 1.346±0.06 g/cm3(Predicted) |
| 酸度系数(pKa) | 7.86±0.10(Predicted) |
|
5-HT 6 Receptor
|
5-HT 7 Receptor
|
5-HT 2A Receptor
|
D 2 Receptor
|
Targeting 5-HT6 and/ or 5-HT7 receptors with antagonist drugs could constitute a promising strategy for treating symptoms of BPSD while avoiding some of the side effects of current antipsychotic drugs. Nevertheless, due to the complex pathology of dementia and accompanying behavioral and psychological symptoms, it seems unlikely that focusing on a single therapeutic target would be sufficient to provide adequate clinical benefit, and it is likely that successful development of novel anti-BPSD agents should involve a “designed” multifactorial approach.